Immunotheranostics in Solid Tumors: Longitudinal Tracking of Human IL13Rα2 CAR-T Cells In Vivo
Journal of Nuclear Medicine · 2025
DOI: 10.2967/jnumed.125.271365 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Hamid Reza Mirzaei und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Interleukin-13 Receptor alpha2 Subunit, Receptors, Chimeric Antigen, T-Lymphocytes, Cell Tracking. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR)-T cell therapy has shown limited success in the treatment of solid tumors, reinforcing the need to elucidate the in vivo biodistribution of these engineered T cells. Here, we integrate the anti-DOTA huC825 reporter ("Thor") platform into newly developed human anti-interleukin-13 receptor α-2 (IL13Rα2)-single-cell fragment variable (scFv)-derived CAR-T cells and investigate its utility for mapping CAR-T cell distribution in a xenograft mouse model of melanoma.
Methods
We engineered anti-IL13Rα2-scFv-derived CAR-T cells expressing huC825 (KLG3BBz-huC825), evaluated detection sensitivity, and monitored CAR-T cell biodistribution via weekly [86Y]Y-aminobenzyl-DOTA PET/CT and therapeutic efficacy.
Results
KLG3BBz-huC825 T cells demonstrated potent antigen-specific cytotoxicity and cytokine release in vitro. The Thor radiohapten capture platform offered exquisite detection sensitivity of only 3,000 engineered T cells and enabled prolonged spatiotemporal assessment of CAR-T cell kinetics up to 7 wk after infusion, corroborated by histopathology. Treatment with KLG3BBz-huC825 resulted in an overall survival benefit.
Conclusion
The Thor platform offers a versatile and highly sensitive approach to study the real-time kinetics of CAR-T cells in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Nuclear Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.
- Molecular Pharmacology Program, Sloan Kettering Institute, New York, New York.
- Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, New York, New York, and Rockefeller University, New York, New York.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
Förderung
- NCI NIH HHS
Zitieren
APA
Mirzaei, H. R., Lovibond, S., Gajecki, L., Qureshy, S., Kumpf, M., Jeanjean, P., Lee, S. G., Cai, W., Miranda, I., Mauguen, A., Carter, L. M., Schöder, H., Veach, D. R., Scheinberg, D. A., & Krebs, S. (2025). Immunotheranostics in Solid Tumors: Longitudinal Tracking of Human IL13Rα2 CAR-T Cells In Vivo. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.271365
Vancouver
Mirzaei HR, Lovibond S, Gajecki L, Qureshy S, Kumpf M, Jeanjean P, et al. Immunotheranostics in Solid Tumors: Longitudinal Tracking of Human IL13Rα2 CAR-T Cells In Vivo. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.125.271365
BibTeX
@article{Mirzaei2025,
author = {Mirzaei, Hamid Reza and Lovibond, Samantha and Gajecki, Leah and Qureshy, Sarah and Kumpf, Melina and Jeanjean, Pauline and Lee, Sang Gyu and Cai, Winson and Miranda, Ileana and Mauguen, Audrey and Carter, Lukas M and Schöder, Heiko and Veach, Darren R and Scheinberg, David A and Krebs, Simone},
title = {Immunotheranostics in Solid Tumors: Longitudinal Tracking of Human IL13Rα2 CAR-T Cells In Vivo},
journal = {Journal of Nuclear Medicine},
year = {2025},
doi = {10.2967/jnumed.125.271365}
}
EUVIMED